ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

AGMB-447

A development code.

Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Agomab Therapeutics NV.

Furthest: phase 2, since Sep 15, 20262 company-led studies, 1 open or runningNext primary completion: Oct 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agomab Therapeutics NV21 open or runningphase 2since Sep 15, 2026Dec 11, 2023Oct 31, 2028phase 2 · NCT07862634

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 11, 2023First study: phase 1 study in IPFFirst studyNCT06181370 · 143 enrolled · United Kingdom
  2. Sep 15, 2026Phase 2 study in Idiopathic Pulmonary FibrosisPhase 2 reachedNCT07862634 · 120 planned

Ahead

  1. Oct 31, 2028Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07862634

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07862634Idiopathic Pulmonary Fibrosis2Not yet recruitingOct 31, 2028120
NCT06181370IPF · United Kingdom1CompletedApr 29, 2026143

How it is read

Names in the registry

  • “AGMB-447”, 2 entries

Codes read as this program: AGMB447.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.